These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 16166328

  • 1. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.
    Dercamp C, Chemin K, Caux C, Trinchieri G, Vicari AP.
    Cancer Res; 2005 Sep 15; 65(18):8479-86. PubMed ID: 16166328
    [Abstract] [Full Text] [Related]

  • 2. CD4(+)CD25(+) regulatory T cells attenuate Hypersensitivity Pneumonitis by suppressing IFN-gamma production by CD4(+) and CD8(+) T cells.
    Park Y, Oh SJ, Chung DH.
    J Leukoc Biol; 2009 Dec 15; 86(6):1427-37. PubMed ID: 19741155
    [Abstract] [Full Text] [Related]

  • 3. CD4+ CD25+ [corrected] regulatory T cells render naive CD4+ CD25- T cells anergic and suppressive.
    Qiao M, Thornton AM, Shevach EM.
    Immunology; 2007 Apr 15; 120(4):447-55. PubMed ID: 17244157
    [Abstract] [Full Text] [Related]

  • 4. Role of bone marrow stromal cells in the generation of human CD8+ regulatory T cells.
    Poggi A, Zocchi MR.
    Hum Immunol; 2008 Nov 15; 69(11):755-9. PubMed ID: 18817823
    [Abstract] [Full Text] [Related]

  • 5. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
    Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L.
    J Exp Med; 2005 Oct 17; 202(8):1075-85. PubMed ID: 16230475
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
    Kosiewicz MM, Alard P, Liang S, Clark SL.
    Int Immunol; 2004 May 17; 16(5):697-706. PubMed ID: 15096489
    [Abstract] [Full Text] [Related]

  • 7. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
    Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ, Goedegebuure PS, Linehan DC.
    Ann Surg Oncol; 2006 Sep 17; 13(9):1252-8. PubMed ID: 16952047
    [Abstract] [Full Text] [Related]

  • 8. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
    Berhanu A, Huang J, Alber SM, Watkins SC, Storkus WJ.
    Cancer Res; 2006 May 01; 66(9):4895-903. PubMed ID: 16651446
    [Abstract] [Full Text] [Related]

  • 9. Basophils can directly present or cross-present antigen to CD8 lymphocytes and alter CD8 T cell differentiation into IL-10-producing phenotypes.
    Kim S, Shen T, Min B.
    J Immunol; 2009 Sep 01; 183(5):3033-9. PubMed ID: 19667092
    [Abstract] [Full Text] [Related]

  • 10. Activation requirements for the induction of CD4+CD25+ T cell suppressor function.
    Thornton AM, Piccirillo CA, Shevach EM.
    Eur J Immunol; 2004 Feb 01; 34(2):366-76. PubMed ID: 14768041
    [Abstract] [Full Text] [Related]

  • 11. Ex vivo activated OVA specific and non-specific CD4+CD25+ regulatory T cells exhibit comparable suppression to OVA mediated T cell responses.
    Li J, Bracht M, Shang X, Radewonuk J, Emmell E, Griswold DE, Li L.
    Cell Immunol; 2006 Jun 01; 241(2):75-84. PubMed ID: 17010326
    [Abstract] [Full Text] [Related]

  • 12. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE.
    Cancer Res; 2005 Aug 01; 65(15):6984-9. PubMed ID: 16061684
    [Abstract] [Full Text] [Related]

  • 13. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.
    Kapp JA, Honjo K, Kapp LM, Xu Xy, Cozier A, Bucy RP.
    Int Immunol; 2006 Nov 01; 18(11):1549-62. PubMed ID: 16966495
    [Abstract] [Full Text] [Related]

  • 14. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.
    Pyzik M, Piccirillo CA.
    J Leukoc Biol; 2007 Aug 01; 82(2):335-46. PubMed ID: 17475784
    [Abstract] [Full Text] [Related]

  • 15. CD8+ T cells produce IL-2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses.
    Kish DD, Gorbachev AV, Fairchild RL.
    J Leukoc Biol; 2005 Sep 01; 78(3):725-35. PubMed ID: 16000396
    [Abstract] [Full Text] [Related]

  • 16. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z, Shi M, Chan T, Sas S, Xu S, Xiang J.
    Cancer Gene Ther; 2007 Jul 01; 14(7):661-75. PubMed ID: 17479109
    [Abstract] [Full Text] [Related]

  • 17. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections.
    Bachmann MF, Wolint P, Walton S, Schwarz K, Oxenius A.
    Eur J Immunol; 2007 Jun 01; 37(6):1502-12. PubMed ID: 17492805
    [Abstract] [Full Text] [Related]

  • 18. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z, Ahmed KA, Hao S, Zhang X, Xie Y, Munegowda MA, Meng Q, Chibbar R, Xiang J.
    Autoimmunity; 2008 Nov 01; 41(7):501-11. PubMed ID: 18855194
    [Abstract] [Full Text] [Related]

  • 19. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
    Xie Y, Bai O, Yuan J, Chibbar R, Slattery K, Wei Y, Deng Y, Xiang J.
    Cancer Res; 2009 Oct 01; 69(19):7756-66. PubMed ID: 19789353
    [Abstract] [Full Text] [Related]

  • 20. Generation of highly suppressive adaptive CD8(+)CD25(+)FOXP3(+) regulatory T cells by continuous antigen stimulation.
    Mahic M, Henjum K, Yaqub S, Bjørnbeth BA, Torgersen KM, Taskén K, Aandahl EM.
    Eur J Immunol; 2008 Mar 01; 38(3):640-6. PubMed ID: 18266270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.